US Patent 8,258,132: Aprepitant Nanoparticle Claims, Expiration, and Patent Landscape
US Patent 8,258,132 covers nanoparticulate formulations of aprepitant, the active ingredient in Merck's Emend product. Its claims require a specific aprepitant particle-size range, defined surface stabilizers, and, for narrower claims, spray-dried or spray-coated dosage forms containing excipients and solid supports. The patent does not cover aprepitant as a chemical entity, all aprepitant formulations, or all neurokinin-1 receptor antagonists.
The patent's effective U.S. patent term ended in 2022 based on its October 26, 2001 priority date. The patent therefore does not create a current U.S. blocking right against generic aprepitant products. Its historical value was directed to particle engineering and oral dosage-form manufacture rather than the underlying aprepitant molecule.
What drug does US Patent 8,258,132 protect?
The claimed compound is aprepitant, chemically identified as a selective neurokinin-1, or NK1, receptor antagonist. Aprepitant is approved for prevention of acute and delayed chemotherapy-induced nausea and vomiting, prevention of postoperative nausea and vomiting, and use in combination regimens for other emesis-related indications.
The patent claims aprepitant in nanoparticulate form. The claim language requires:
- Apportionment of aprepitant into particles with an effective average particle size below 400 nanometers;
- A surface stabilizer adsorbed to the particle surface;
- Use of hydroxypropyl cellulose-super low viscosity, sodium lauryl sulfate, or both as the claimed stabilizer;
- Optional redispersing agents, solid supports, carriers, and lubricants;
- Pharmaceutical administration for NK1 receptor antagonism or treatment of emesis.
The patent does not claim the basic aprepitant molecule by itself. Earlier composition-of-matter patents cover the active pharmaceutical ingredient and related stereochemical structures.
What are the independent claims in US 8,258,132?
Claims 1, 3, 4, 6, and 9-10 contain the principal independent claim categories.
| Claim |
Claim category |
Core limitation |
| 1 |
Nanoparticulate composition |
Aprepitant particles below 400 nm with hydroxypropyl cellulose-super low viscosity or sodium lauryl sulfate |
| 3 |
Pharmaceutical composition |
Claim 1 composition plus a pharmaceutically acceptable carrier |
| 4 |
Solid-supported dosage form |
Claim 1 composition spray-dried or spray-coated onto a solid support |
| 6 |
Formulated composition |
Aprepitant below 400 nm with stabilizer, redispersing agent, and solid support |
| 9 |
Method of use |
Administration for antagonizing substance P or blocking NK1 receptors |
| 10 |
Method of treatment |
Administration for treating emesis |
Claims 2, 5, 7, and 8 narrow those categories by adding particle-size, support, and quantitative composition limitations.
How broad is claim 1?
Claim 1 is narrower than a general nanoparticulate aprepitant claim but broad enough to cover multiple oral solid dosage-form development strategies.
A potentially infringing product would need to satisfy all of the following elements:
- The active ingredient must be the claimed aprepitant stereoisomer or a pharmaceutically acceptable salt.
- The aprepitant must be present as a nanoparticulate composition.
- The effective average particle size must be below 400 nm.
- At least one specified surface stabilizer must be adsorbed on the particle surface.
- The stabilizer must be hydroxypropyl cellulose-super low viscosity, sodium lauryl sulfate, or both.
A formulation using a different stabilizer, such as povidone, poloxamer, lecithin, or hypromellose, would not literally satisfy the stabilizer limitation. A formulation with particles at or above 400 nm would not literally satisfy the particle-size limitation.
The claim does not require a particular tablet strength, capsule strength, dissolution profile, dosage regimen, manufacturing process, or therapeutic indication. Those omissions increase the potential scope of claim 1 within the defined formulation class.
What particle-size limitations apply?
The claims use two principal particle-size thresholds:
| Claim |
Particle-size limitation |
| 1 |
Less than 400 nm |
| 2 |
Less than 250 nm |
| 6 |
Less than 400 nm |
| 7 |
Less than 400 nm |
| 8 |
Less than 400 nm |
"Effective average particle size" normally requires assessment of a representative particle-size distribution rather than reliance on a single unusually small particle. In an enforcement dispute, the analytical method, sample preparation, agglomeration state, measurement instrument, and reporting convention would be material.
Claim 2 is narrower than claim 1 because every composition below 250 nm also falls below 400 nm, while the reverse is not true. Claims 7 and 8 add percentage ranges but do not independently narrow the stabilizer class beyond the limitations incorporated from claim 6.
What formulations are protected by US 8,258,132?
The patent covers several formulation architectures.
Nanoparticulate aprepitant with surface stabilizer
This is the broadest technical category. It requires aprepitant particles below 400 nm and one of the two specified stabilizers. Claim 1 does not require a solid support or a particular dosage form.
Spray-dried or spray-coated compositions
Claim 4 covers a composition in which the nanoparticulate material is spray dried or spray coated onto a solid support. Claim 5 identifies:
- Microcrystalline cellulose spheres;
- Sugar-starch spheres;
- Lactose spheres.
These claims are directed to an intermediate or final dosage-form structure in which the nanoparticulate drug is deposited on a particulate carrier.
Quantified solid formulations
Claim 7 recites the following ranges:
| Component |
Claimed range |
| Aprepitant |
About 5%-60% by weight |
| Surface stabilizer |
About 1%-20% |
| Redispersing agent |
About 0%-50% |
| Solid support |
About 0%-90% |
| Lubricant |
About 0%-5% |
Claim 8 narrows the aprepitant range to about 25%-50%, the surface stabilizer to about 5%-15%, and the solid support to about 10%-50%. It retains the 0%-50% redispersing-agent and 0%-5% lubricant ranges.
The use of "about" creates ordinary claim-construction issues regarding acceptable variation around each endpoint. The ranges also create potential overlap questions where a formulation contains additional excipients not expressly listed.
Does US 8,258,132 cover Emend?
The patent is relevant to nanoparticulate aprepitant formulations, but the existence of a patent does not establish that the commercial Emend product practices every claim.
Emend has been marketed in multiple dosage forms and strengths. A product-by-product infringement analysis would require the relevant product formulation, particle-size data, excipient composition, manufacturing process, and regulatory filing. Public labeling generally does not disclose all information needed to determine whether a formulation has sub-400-nanometer aprepitant particles or whether a specified stabilizer is adsorbed on the particle surface.
The patent is therefore best characterized as a formulation-specific aprepitant patent, not as a complete patent on Emend.
When did US Patent 8,258,132 expire?
US Patent 8,258,132 issued on September 4, 2012. Its priority date is October 26, 2001. Applying the 20-year term applicable to a utility patent with that priority date, the base term ended on October 26, 2022, subject to any patent-term adjustment reflected in the USPTO patent record.
The patent is no longer a current U.S. patent-term barrier to generic entry. Any historical patent-term adjustment would need to be checked against the USPTO continuity and patent-term records, but it would not change the conclusion that the patent is expired as of 2026.
| Event |
Date |
| Earliest claimed priority |
October 26, 2001 |
| U.S. issue date |
September 4, 2012 |
| Base 20-year expiration |
October 26, 2022 |
| Status in 2026 |
Expired by term |
Patent expiration does not erase potential exposure for conduct occurring before expiration. It also does not eliminate independent protection that may have existed under other aprepitant patents.
What is the Orange Book status of US 8,258,132?
US Patent 8,258,132 should not be treated as the principal Orange Book patent protecting the aprepitant active ingredient. Orange Book listing depends on whether the patent claims the approved drug substance, drug product, or an approved method of use and whether the sponsor submitted the patent for listing under FDA regulations.
A nanoparticle formulation patent may be eligible for listing if it claims the approved drug product or a qualifying formulation. A method-of-use claim may be listed only where it corresponds to an approved indication. Listing status and patent validity are separate issues.
The relevant Orange Book analysis should distinguish:
- Drug-substance patents covering aprepitant;
- Drug-product or formulation patents;
- Method-of-use patents for approved nausea and vomiting indications;
- Patents that were delisted, expired, or omitted from later Orange Book editions.
FDA Orange Book data, rather than the patent document alone, controls the formal listing analysis. The patent's expiration in 2022 means it cannot impose a current patent-based delay on an ANDA applicant.
How does US 8,258,132 compare with aprepitant composition-of-matter patents?
US 8,258,132 is weaker in commercial blocking power than the core aprepitant composition-of-matter patents because it covers a particular formulation technology rather than the active molecule.
| Patent category |
Protected subject matter |
Generic-entry significance |
| Composition of matter |
Aprepitant chemical structure and stereochemistry |
Highest during term; can block products using the active ingredient |
| Salt or polymorph |
Specific solid-state or salt form |
Depends on the generic's form |
| Nanoparticle formulation |
Sub-400-nm aprepitant with specified stabilizers |
Applies only to qualifying formulations |
| Spray-supported formulation |
Nanoparticles deposited on specified supports |
Narrower manufacturing and dosage-form coverage |
| Method of use |
NK1 antagonism or emesis treatment |
Relevant only to claimed indications and use instructions |
Once the core active-ingredient patents expired, generic manufacturers could develop aprepitant products using alternative particle sizes, stabilizers, carriers, or manufacturing processes. The nanoparticle patent could have required a design-around even after core composition patents expired, but it does not present that barrier today.
What was the patent landscape for generic aprepitant?
Aprepitant generic entry depended on more than one patent family. The principal risk categories were:
- Core chemical patents covering aprepitant;
- Formulation patents covering particle engineering and oral dosage forms;
- Method-of-use patents covering chemotherapy-induced and postoperative emesis;
- Regulatory exclusivity associated with FDA approval;
- Product-specific patents listed for capsules, oral suspensions, or injectable formulations.
Generic applicants using an ANDA could address listed patents through certification under section 505(j)(2)(A)(vii) of the Federal Food, Drug, and Cosmetic Act. A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. A Paragraph III certification would defer approval until patent expiration.
For an aprepitant product, the practical Paragraph IV analysis would require comparison of:
- Particle-size distribution;
- Stabilizer identity and concentration;
- Adsorption to the drug-particle surface;
- Presence of a redispersing agent;
- Solid-support material;
- Spray-drying or spray-coating steps;
- Approved indication and labeling.
A generic applicant could seek to avoid the claims by using a non-listed stabilizer, a larger particle size, a different solid-state process, or a formulation that does not contain the claimed solid support.
Which companies challenged or competed with Emend?
Merck was the originator and principal commercial sponsor of Emend. Generic competition later included companies such as Teva and Viatris/Mylan, among other ANDA sponsors. The competitive field also included alternative antiemetic products and combination regimens, including:
- Rolapitant, marketed as Varubi;
- Netupitant/palonosetron, marketed as Akynzeo;
- Fosaprepitant, marketed as a parenteral prodrug formulation of aprepitant;
- Palonosetron and other 5-HT3 antagonists;
- Olanzapine-containing antiemetic regimens;
- Dexamethasone-based supportive-care combinations.
These products do not necessarily practice the claims of US 8,258,132 because the claims are directed to nanoparticulate aprepitant formulations, not to the broader antiemetic market.
What litigation and settlement issues affect this patent?
A patent-specific litigation conclusion requires the federal court docket and any ANDA case tied to the patent. The patent document alone does not establish whether a Paragraph IV notice, district-court action, consent judgment, covenant not to sue, or settlement agreement existed.
The legal issues most likely to control a dispute under the claims include:
- Whether the accused formulation contains aprepitant particles below 400 nm;
- Whether the stabilizer is adsorbed on the particle surface;
- Whether hydroxypropyl cellulose-super low viscosity is present in the claimed form;
- Whether sodium lauryl sulfate performs the claimed surface-stabilizing function;
- Whether a spray-drying or spray-coating process is used;
- Whether a solid support falls within claim 5;
- Whether the claims are anticipated or obvious in view of prior nanoparticulate drug technology;
- Whether the specification adequately supports the full particle-size and composition ranges;
- Whether the method claims are induced by the approved label.
Because the patent expired in 2022, a new infringement action based solely on post-expiration commercial activity would not provide a live exclusionary remedy.
How strong is the patent estate for aprepitant?
The US 8,258,132 patent had moderate historical strength as a formulation patent and low current blocking strength because it is expired.
Historical strengths
- Claims identify a defined active ingredient.
- Claim 1 includes both a particle-size threshold and specified stabilizers.
- Claims 4-8 cover practical solid dosage-form embodiments.
- The patent includes method claims tied to recognized NK1 and emesis indications.
- The formulation could potentially improve dissolution or oral performance compared with poorly soluble crystalline aprepitant.
Historical weaknesses
- The claims are limited to two expressly named stabilizers.
- Particle-size measurements can generate reproducibility and claim-construction disputes.
- Nanoparticulate drug delivery was a developed technical field before the priority date.
- Broad particle-size and excipient ranges may face written-description, enablement, or obviousness challenges.
- The patent does not cover every aprepitant formulation or every commercial presentation.
- Method claims are vulnerable to non-infringing labeling and substantial non-infringing-use arguments.
Current strength
The patent has no meaningful current exclusionary value in the United States because its term has ended. Its remaining business relevance is historical, freedom-to-operate analysis for pre-expiration activity, and assessment of whether related continuation or divisional patents had separate terms.
What generic launch risks remain?
For a current U.S. generic aprepitant launch, US 8,258,132 presents no active patent-term risk. The remaining risks are more likely to arise from:
- Other unexpired or later-filed formulation patents;
- Separate patents covering injectable or prodrug products;
- Regulatory requirements for bioequivalence;
- Product-specific formulation differences;
- Trade secrets involving manufacturing and particle-size control;
- Patent rights outside the United States;
- Litigation over earlier sales or pre-expiration conduct.
A generic using a conventional capsule or suspension formulation would not automatically infringe this patent merely because it contains aprepitant. The claim requires the defined nanoparticulate and stabilizer limitations.
Does the patent create biosimilar risk?
No. Aprepitant is a small-molecule drug, not a biologic. The relevant regulatory pathway is an ANDA under section 505(j), not a biosimilar application under section 351(k) of the Public Health Service Act.
The correct competitive terms are generic aprepitant, authorized generic, alternative formulation, and therapeutic substitute. Biosimilar concepts such as reference-product exclusivity, interchangeability, and patent dance procedures do not apply to this patent.
What manufacturing and intellectual-property barriers does the patent cover?
The technical barriers are concentrated in nanoparticle production and dosage-form conversion.
Potentially relevant process steps include:
- Wet milling or high-energy particle-size reduction;
- Stabilizer adsorption at the drug-particle interface;
- Control of agglomeration during processing;
- Redispersion after drying;
- Spray drying or spray coating onto multiparticulate supports;
- Uniform deposition on microcrystalline cellulose, sugar-starch, or lactose spheres;
- Lubrication and compression or encapsulation.
The patent claims are primarily product and product-by-process adjacent claims. A manufacturer could avoid them by changing the stabilizer, particle-size profile, drying method, support material, or dosage-form architecture. Manufacturing know-how may remain commercially valuable even after patent expiration, but it is separate from the patent's legal exclusivity.
Key Takeaways
- US Patent 8,258,132 covers nanoparticulate aprepitant formulations, not aprepitant generally.
- Claim 1 requires particles below 400 nm and hydroxypropyl cellulose-super low viscosity or sodium lauryl sulfate as a surface stabilizer.
- Claim 2 narrows the particle-size threshold to below 250 nm.
- Claims 4-8 cover spray-supported and quantitatively defined solid formulations.
- Claims 9-10 cover NK1 receptor antagonism and treatment of emesis.
- The patent's base term ran from the October 26, 2001 priority date to October 26, 2022.
- The patent is expired in the United States as of 2026.
- It does not create a current Paragraph IV or generic-launch barrier.
- It is not a biosimilar patent and does not concern a biologic product.
- Current aprepitant freedom-to-operate analysis must focus on other patent families, product-specific patents, and non-patent manufacturing barriers.
FAQs
Is US 8,258,132 a composition-of-matter patent for aprepitant?
No. It is a formulation patent covering specified nanoparticulate aprepitant compositions and related pharmaceutical and method-of-use claims.
Can a generic aprepitant product use nanoparticles after US 8,258,132 expired?
Yes. The patent no longer prevents nanoparticulate aprepitant development in the United States. Other unexpired patents could still matter.
Does sodium lauryl sulfate alone satisfy the stabilizer limitation?
The claim expressly identifies sodium lauryl sulfate as a qualifying surface stabilizer. Infringement would still require the other limitations, including the claimed aprepitant particle size and surface adsorption.
Does a sub-250-nanometer aprepitant product infringe claim 2 automatically?
No. It must also contain the claimed aprepitant compound and satisfy the required surface-stabilizer limitation. Particle size alone is insufficient.
Is an aprepitant injectable product covered by these claims?
Not automatically. The claims focus on nanoparticulate aprepitant compositions and specified solid-supported or pharmaceutical formulations. An injectable product would require a separate element-by-element analysis.
References
-
U.S. Patent No. 8,258,132. (2012). Nanoparticulate aprepitant formulations. United States Patent and Trademark Office.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (2024). Emend (aprepitant) prescribing information. FDA.
-
United States Code. 21 U.S.C. § 355(j). Abbreviated new drug applications.
-
United States Code. 35 U.S.C. § 154. Contents and term of patent; provisional rights.
